Igenica Inc, the biopharmaceutical firm dedicated to developing antibodies and antibody-drug conjugates to treat the Big C, obtained $14 million in its Series C extension round.
The Column Group
Breaking News
Subscribe to VCpost newsletter
Most Popular
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Brazilian Woman Wheels Her Dead Uncle Into the Bank to Withdraw Loan in His Name
- Trump Media’s First Auditor Quits After Just a Few Months on the Job: Report
- Tesla Spends $200,000 in Promoting Elon Musk's Social Media Platform X Following Mention of 'Minimal Advertising Efforts'
- UPDATE: Google Employees Arrested and Fired After Staging Protests Over Company's Project Nimbus Deal With Israel
- Social Security Benefits: 2025 COLA Predicted to Increase Amid Rising Inflation
- Spirit Airlines Staff at Florida Airport Filmed Cursing a 'Karen' Passenger After Moaning About Her Flight
- Navigating Tariff Tides: A Conversation with Jim Pratt on Supply Chain Strategies Ahead of 2024 Elections
